Anatara Receives Ethics Approval to Start IBS Trial
Melbourne, Feb 8, 2021 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D).
Highlights:
- Study will evaluate safety and efficacy of GaRP in patients with IBS (irritable bowel syndrome)
- Study design is Randomised, Double-Blinded and Placebo-Controlled to address future evidence-based claims
- Virtual study with ObvioHealth Australia to provide digital clinical trial platform "ClaimIt"
- Supported by leading CROs: GenesisCare Clinical CRO, Microba, Sonic Clinical Trials
Ethics approval is confirmation Anatara has completed the necessary pre-clinical safety and efficacy testing of GaRP required to commence human clinical studies. Now that HREC approval of the protocol has been received, we are able to immediately undertake site initiation procedures a prerequisite for patient recruitment which is planned for March 2021.
This randomised, double-blind, placebo-controlled study will be conducted in two stages as a virtual study using ObvioHealth Australia's ClaimIt platform. This involves minimal on-site visits and participants completing most assessments online. Up to 6 sites will be established by Sonic Clinical Trials and approximately 200 participants enrolled. GenesisCare Clinical CRO will provide medical advisory and medical monitoring services whereas Microba will provide microbiome testing using shotgun metagenomic sequencing and proprietary bioinformatics.
The study design consists of two stages (Stage 1, Stage 2), with an interim analysis between stages. Stage 1 will assess the safety, tolerability and efficacy of two different strengths of GaRP against placebo in a 1:1:1 randomisation protocol. Following interim analysis, one dose will be selected, and the remaining participants recruited in a 1:1 randomisation protocol. Of the 200 planned participants, at least 90 will enrol in stage 1, and 110 participants will enrol in stage 2. For each participant in each stage, the study will last for 12 weeks; including 8 weeks of treatment, preceded by a 2-week screening/baseline period and followed by a 2-week washout period. Measurements will include a number of surveys including the IBS specific surveys: IBS-SSS (severity scoring system), IBS QoL (quality of life) and IBS-AR (adequate relief) and Bristol Stool Form Scale.
CEO Steve Lydeamore commented, "There is a major unmet need and significant market opportunity for an evidence-based complementary medicine for IBS. Human ethics approval is another milestone for Anatara and clinicians and patients seeking effective remedies to address IBS. Anatara's GaRP has demonstrated that it has the potential to manage the devastating symptoms experienced by IBD and IBS patients, by addressing processes that contribute to the pathophysiology of these chronic bowel conditions."
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
